End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta. - Lu ER; Hoo CPL; Cheung HM; Wong IWC; Fung KFK; Chang SLY; Lee ACW; Fu ECH; Ku DTL; Yau JPW; Shing MMK; Mak CYK; et al. (Cancers, 2026)